<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Specific activating mutations within the epidermal growth factor receptor (EGFR) identify a subset of <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancers</z:e> with dramatic sensitivity to the specific <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> (TKI), <z:chebi fb="0" ids="49668">gefitinib</z:chebi> and <z:chebi fb="0" ids="114785">erlotinib</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the abundant expression of EGFR protein in a broad range of epithelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, EGFR mutations have not been reported in a substantial fraction of other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Given recent reports of TKI-responsive cases of esophageal and <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo>, this study was designed to determine the prevalence of EGFR mutations in these <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: We sequenced exons 18 to 21 of EGFR from 21 cases of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, 5 cases of high-grade <z:mp ids='MP_0000467'>esophageal dysplasia</z:mp>, 17 cases of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and 55 cases of <z:hpo ids='HP_0006725'>pancreatic adenocarcinoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Subsets of esophageal (n = 7) and <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> cases (n = 5) were obtained from patients who were subsequently treated with <z:chebi fb="0" ids="49668">gefitinib</z:chebi> or <z:chebi fb="0" ids="114785">erlotinib</z:chebi>-<z:chebi fb="0" ids="31348">capecitabine</z:chebi>, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Mutations of EGFR were identified in two <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancers</z:e> (11.7%), three cases of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (14.2%), and two <z:hpo ids='HP_0002894'>pancreatic cancers</z:hpo> (3.6%) </plain></SENT>
<SENT sid="6" pm="."><plain>The mutations consisted of the recurrent missense L858R and in-frame deletion delE746-A750, previously characterized as activating EGFR mutations in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>We also identified the TKI drug resistance-associated EGFR T790M mutation in an untreated case of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and the corresponding <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The presence of activating mutations within EGFR in both esophageal and <z:hpo ids='HP_0006725'>pancreatic adenocarcinomas</z:hpo> defines a previously unrecognized subset of <z:e sem="disease" ids="C0017185" disease_type="Neoplastic Process" abbrv="">gastrointestinal tumors</z:e> in which EGFR signaling may play an important biological role </plain></SENT>
<SENT sid="9" pm="."><plain>EGFR mutations in <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesions</z:e> of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> also point to these as an early event in transformation of the esophageal epithelium </plain></SENT>
<SENT sid="10" pm="."><plain>The role of genotype-directed TKI therapy should be tested in prospective clinical trials </plain></SENT>
</text></document>